Retrospective analysis of imaging modalities acquired during clinical diagnosis of patients with clinical suspected neurodegenerative Parkinsonian syndrome
- Conditions
- G20Parkinson disease
- Registration Number
- DRKS00016920
- Lead Sponsor
- Klinik und Poliklinik für Nuklearmedizin, LMU München
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
clinical suspected neurodegenerative Parkinsonian Syndrome and acquisition of at least one of the following modalities: cMRI, OCT, tau-PET
Exclusion Criteria
other non-neurodegenerative CNS diseases like glioma or stroke
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method For patients with cMRT the midbrain diameter and the midbrain to pons ratio will be acquired.<br><br>For patients with OCT the thickness of retinal layers will be accessed.<br><br>For patients with tau-PET the regional signal in defined target regions (midbrain, globus pallidus, nucleus dentatus, frontal cortex) will be quantified.<br><br>The quantification will be performed retrospectively and linked to the acqusition date. Specific software will be used for quantification (i.e. PMOD Technologies, Basel, Switzerland).<br><br>The primary endpoint consists in correlation of cMRI, OCT, and tau-PET quantification with disease severity for patients with Progressive Supranuclear Palsy.
- Secondary Outcome Measures
Name Time Method Quantification of cMRI, OCT, and tau-PET will be compared between patients with probable and possible Progressive Supranuclear Palsy, patients with probable tau-negative Parkinsonian syndrome and healthy controls.